27.62 USD
-0.25 (-0.9%)
27.62 USD
0 (0%)
Overall ACAD gets a fundamental rating of 5 out of 10. We evaluated ACAD against 530 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
In the past 5 years ACAD always reported negative net income.
ACAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ACAD (19.63%) is better than 96.79% of its industry peers.
ACAD has a Return On Equity of 28.47%. This is amongst the best in the industry. ACAD outperforms 97.55% of its industry peers.
ACAD's Return On Invested Capital of 7.66% is amongst the best of the industry. ACAD outperforms 93.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 24.94%, ACAD belongs to the top of the industry, outperforming 94.91% of the companies in the same industry.
With an excellent Operating Margin value of 9.02%, ACAD belongs to the best of the industry, outperforming 91.13% of the companies in the same industry.
Looking at the Gross Margin, with a value of 91.92%, ACAD belongs to the top of the industry, outperforming 93.21% of the companies in the same industry.
ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACAD has an Altman-Z score of 6.32. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD's Altman-Z score of 6.32 is fine compared to the rest of the industry. ACAD outperforms 74.91% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.32 |
ROIC/WACC0.87
WACC8.79%
2.3 Liquidity
A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
ACAD has a worse Current ratio (3.02) than 64.34% of its industry peers.
ACAD has a Quick Ratio of 2.94. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a worse Quick ratio (2.94) than 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
The Earnings Per Share is expected to grow by 38.78% on average over the next years. This is a very strong growth
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.04% yearly.
EPS Next Y73.59%
EPS Next 2Y30.49%
EPS Next 3Y32.59%
EPS Next 5Y38.78%
Revenue Next Year11.07%
Revenue Next 2Y11.24%
Revenue Next 3Y10.99%
Revenue Next 5Y10.04%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 41.22, ACAD can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.32% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.57, ACAD is valued quite expensively.
ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 33.79.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 92.08% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, ACAD is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.22 | ||
| Fwd PE | 33.79 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 93.02% of the companies in the same industry.
ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 94.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.46 | ||
| EV/EBITDA | 30.23 |
4.3 Compensation for Growth
ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
ACAD's earnings are expected to grow with 32.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y30.49%
EPS Next 3Y32.59%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
27.62
-0.25 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.36%
Inst Owner Change1.37%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.67B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target29.85 (8.07%)
Short Float %5.32%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)0.36%
PT rev (3m)-2.82%
EPS NQ rev (1m)-8.21%
EPS NQ rev (3m)6.23%
EPS NY rev (1m)42.81%
EPS NY rev (3m)44.68%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)2.32%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 41.22 | ||
| Fwd PE | 33.79 | ||
| P/S | 4.46 | ||
| P/FCF | 21.46 | ||
| P/OCF | 14.71 | ||
| P/B | 5.09 | ||
| P/tB | 5.8 | ||
| EV/EBITDA | 30.23 |
EPS(TTM)0.67
EY2.43%
EPS(NY)0.82
Fwd EY2.96%
FCF(TTM)1.29
FCFY4.66%
OCF(TTM)1.88
OCFY6.8%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.56
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 6.32 |
F-Score4
WACC8.79%
ROIC/WACC0.87
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y73.59%
EPS Next 2Y30.49%
EPS Next 3Y32.59%
EPS Next 5Y38.78%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.24%
Revenue Next 3Y10.99%
Revenue Next 5Y10.04%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 73.59% in the next year.